PNR
59
-3
PRGO
32
-4
DD
42
-3
KR
50
-2
BAX
39
-2
SWK
50
-2
FLR
50
-2
FIS
45
-3
EMC
39
-3
PNW
55
-2
GM
61
-2
HSIC
45
-3
MAC
53
-5
EL
25
-2
O
15
-11
WFC
58
-2
MCO
71
-2
YUM
42
-3
DG
14
-2
AVB
54
-3
PNR
59
-3
PRGO
32
-4
DD
42
-3
KR
50
-2
BAX
39
-2
SWK
50
-2
FLR
50
-2
FIS
45
-3
EMC
39
-3
PNW
55
-2
GM
61
-2
HSIC
45
-3
MAC
53
-5
EL
25
-2
O
15
-11
WFC
58
-2
MCO
71
-2
YUM
42
-3
DG
14
-2
AVB
54
-3
Financhill
Back

Arcutis Biotherapeutics 10K Form

Buy
55

ARQT
Arcutis Biotherapeutics

Last Price:
$14.31
Seasonality Move:
42.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ARQT News And Ratings

See the #1 stock for the next 7 days that we like better than ARQT

ARQT Financial Statistics

Sales & Book Value

Annual Sales: $59.6M
Cash Flow: $-34.8M
Price / Cash Flow: 0
Annual Sales: $1.34
Price / Book: 10.69

Profitability

EPS (TTM): -1.79000
Net Income (TTM): $-195.5M
Gross Margin: $54.6M
Return on Equity: -138.99%
Return on Assets: -49.01%

Arcutis Biotherapeutics Earnings Forecast

Key Arcutis Biotherapeutics Financial Ratios

  • The Gross Profit Margin over the past 4 years for ARQT is 91.63%.
  • The Selling, General & Administrative Expenses for ARQT have been equal to 310.61% of Gross Profit Margin.
  • The Research & Development expenses have been 185.51% of Revenue.
  • The Interest Expense is -11.33% of Operating Income.
  • The Net Earning history of ARQT is -439.79% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 1 years.

Arcutis Biotherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ARQT
CUSIP: 03969K
Website: arcutis.com

Debt

Debt-to-Equity Ratio: 1.31
Current Ratio: 2.46
Quick Ratio: 2.27

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ARQT Technical Analysis vs Fundamental Analysis

Buy
55
Arcutis Biotherapeutics (ARQT) is a Buy

Is Arcutis Biotherapeutics a Buy or a Sell?